Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2020
Period Ending	Aug '25 Aug 12, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2020
Market Capitalization	1,894	1,298	2,124	1,491	3,167	-	Upgrade
Market Cap Growth	2.24%	-38.88%	42.42%	-52.91%	-	-	Upgrade
Enterprise Value	1,692	1,193	1,921	1,291	2,856	-	Upgrade
Last Close Price	10.51	7.51	11.30	7.74	16.07	-	Upgrade
PE Ratio	64.87	43.32	152.20	-	-	-	Upgrade
Forward PE	13.77	13.19	25.06	26.54	150.33	-	Upgrade
PS Ratio	2.63	1.90	3.21	2.40	5.51	-	Upgrade
PB Ratio	9.75	13.92	12.58	10.47	16.03	-	Upgrade
P/TBV Ratio	58.19	-	45.58	47.27	31.86	-	Upgrade
P/FCF Ratio	14.48	12.99	22.91	28.82	74.66	-	Upgrade
P/OCF Ratio	11.55	9.57	17.08	20.20	58.48	-	Upgrade
EV/Sales Ratio	2.40	1.75	2.91	2.08	4.97	-	Upgrade
EV/EBITDA Ratio	40.72	24.35	58.74	-	-	-	Upgrade
EV/EBIT Ratio	59.22	28.64	77.08	-	-	-	Upgrade
EV/FCF Ratio	12.94	11.94	20.72	24.95	67.34	-	Upgrade
Debt / Equity Ratio	0.07	0.09	0.05	0.08	-	-1.09	Upgrade
Debt / EBITDA Ratio	0.32	0.15	0.25	-	-	8.75	Upgrade
Debt / FCF Ratio	0.11	0.08	0.10	0.22	-	6.32	Upgrade
Asset Turnover	1.56	1.66	1.55	1.48	1.68	2.08	Upgrade
Quick Ratio	0.74	0.58	0.90	0.82	1.10	0.62	Upgrade
Current Ratio	0.78	0.72	1.04	0.97	1.16	0.67	Upgrade
Return on Equity (ROE)	22.58%	22.86%	8.97%	-28.67%	-	-	Upgrade
Return on Assets (ROA)	3.96%	6.34%	3.65%	-6.20%	-15.40%	14.32%	Upgrade
Return on Capital (ROIC)	12.89%	18.67%	9.40%	-14.77%	-44.01%	81.77%	Upgrade
Return on Capital Employed (ROCE)	13.20%	38.50%	13.60%	-	-	99.40%	Upgrade
Earnings Yield	1.52%	2.31%	0.66%	-3.27%	-3.43%	-	Upgrade
FCF Yield	6.90%	7.70%	4.37%	3.47%	1.34%	-	Upgrade
Buyback Yield / Dilution	7.47%	5.94%	0.72%	-21.31%	-26.85%	1.00%	Upgrade

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q